Superoxide Dismutase 2 protein levels in blood may act as a prognostic marker for high-risk neuroblastoma patients.


Creative Commons License

Demir A. B., Altun Z. S., Aktaş S., Olgun H. N.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, vol.7, no.1, pp.196-213, 2023 (ESCI)

Abstract

Purpose: Determination of proteomic differences plays an important role in biomarker investigations. Due to its heterogenic molecular background, identification of certain biomarkers is still a demand both for diagnosis and prognosis of neuroblastoma. In this study, it is aimed to identify marker proteins/mechanisms that may play role in neuroblastoma prognosis. Material and Methods: Real-time PCR analyses were performed for 2p24.3, 11q23, 1p36 and 17q25 status from tumor samples of the patients to determine the risk groups. A proteomic approach was used for different risk groups of the disease by using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF/TOF) approach. Mononuclear cell pools from blood samples of patients for different risk groups were constructed and protein expression changes for different groups were identified. Results: Manganese-superoxide dismutase (SOD2) protein was found to significantly increase in highrisk group of neuroblastoma patients. Conclusion: Our results showed that SOD2 may play an important role in neuroblastoma progression and be a candidate prognostic peripheral blood marker for neuroblastoma patients.